Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Molecular Profile CD274 positive
Therapy Pembrolizumab
Indication/Tumor Type triple-receptor negative breast cancer
Response Type sensitive


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive triple-receptor negative breast cancer sensitive Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase III trial (KEYNOTE-355) that supported FDA approval, addition of Keytruda (pembrolizumab) to chemotherapy significantly improved progression-free survival compared to chemotherapy alone (9.7 vs 5.6, HR=0.65, p=0.0012) in patients with locally recurrent or metastatic triple-receptor negative breast cancer expressing CD274 (PD-L1, CPS>=10), as determined by an FDA-approved test (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1000-1000; NCT02819518). detail... detail... detail...
CD274 positive triple-receptor negative breast cancer sensitive Pembrolizumab Guideline Actionable The combination of Keytruda (pembrolizumab) plus chemotherapy such as Taxol (paclitaxel), Abraxane (nab-paclitaxel), or Paraplatin (carboplatin) plus Gemzar (gemcitabine) is included in guidelines as first line therapy for CD274 (PD-L1)-positive patients with triple-negative breast cancer (PMID: 34678411; detail... 34678411
PubMed Id Reference Title Details
ESMO Clinical Practice Guidelines Full reference...
Full reference...
Keytruda (pembrolizumab) FDA Drug Label Full reference...
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Full reference...
(34678411) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Full reference...